Exploring Inhibrx, Inc. (INBX) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Inhibrx, Inc. (INBX) and what's driving their decisions? As of December 31, 2024, a significant 76.89% of Inhibrx's shares are held by institutional investors, reflecting substantial confidence from major players in the financial world. With key developments like the promising Phase 1 trial data for ozekibart (INBRX-109) showing a complete response in one patient with colorectal cancer, and a net income of $1.69 billion for the full year 2024, are these factors influencing investor behavior? Let's delve into the details of Inhibrx's investor profile, exploring the major shareholders and the strategic moves behind their investments.

Inhibrx, Inc. (INBX) Who Invests in Inhibrx, Inc. (INBX) and Why?

Understanding the investor profile of Inhibrx, Inc. (INBX) provides valuable insights into the market's perception of the company. By examining the types of investors, their motivations, and typical investment strategies, a clearer picture emerges of what drives interest in this clinical-stage biopharmaceutical company.

Here's a breakdown of Inhibrx, Inc.'s (INBX) investor landscape:

The ownership structure of Inhibrx, Inc. (INBX) includes a mix of:

• Institutions: A significant portion of Inhibrx's shares are held by institutional investors. As of December 31, 2024, institutional ownership stood at 76.89%. These major institutions are firms that manage assets exceeding $100 million and include financial holdings companies, banks, insurance companies, mutual fund managers, and self-managed pension and endowment funds.
• Hedge Funds: Hedge funds also hold a notable percentage of Inhibrx's stock.
• VC/PE Firms: Venture Capital and Private Equity firms have positions in Inhibrx.
• Public Companies: Other public companies may hold shares of Inhibrx.
• Individual Insiders: Individuals with close ties to the company, such as board members and executives, also own shares.
• General Public: Retail investors also form a part of Inhibrx's investor base.

The largest shareholders in Inhibrx, Inc. (INBX) include:

• Viking Global Investors Lp
• Sanofi
• Perceptive Advisors Llc
• BlackRock, Inc.
• HighTower Advisors, LLC
• Vanguard Group Inc
• Walleye Capital LLC
• Sofinnova Investments, Inc.
• Slotnik Capital, LLC
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares

As of December 31, 2024, Viking Global Investors LP held 1,787,705 shares. Sanofi held 1,157,926 shares, a new position. Perceptive Advisors Llc held 1,064,026 shares.

Investors are attracted to Inhibrx, Inc. (INBX) for several key reasons:

• Innovative Therapies: Inhibrx is focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and rare diseases.
• Private Placement Financing: Inhibrx has secured significant private placement financing, with existing investors like RA Capital Management, Viking Global Investors, and Perceptive Advisors participating. In August 2023, a private placement financing was expected to result in gross proceeds of approximately $200 million.
• Strategic Loan Agreements: In January 2025, Inhibrx entered into a loan and security agreement with Oxford Finance for up to $150 million. An initial term loan of $100 million was funded, with an additional $50 million potentially available.
• Acquisition Interest: In January 2024, Sanofi agreed to acquire Inhibrx, which added a potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to its pipeline. Sanofi acquired all outstanding shares of Inhibrx for $30.0 per share in cash, representing an equity value of approximately $1.7 billion (on a fully diluted basis).

Typical investment strategies seen among investors in Inhibrx, Inc. (INBX) include:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, as evidenced by the institutional ownership.
• Growth Prospects: Investors are drawn to Inhibrx's potential for growth, driven by its pipeline of therapeutic candidates and focus on oncology and rare diseases.

Institutional ownership in Inhibrx Biosciences, Inc. shows current positions in the company by institutions and funds, as well as latest changes in position size. As of April 14, 2025, the share price was $11.88 per share. Previously, on April 15, 2024, the share price was $34.74 per share, representing a decline of 65.80% over that period.

For more insights into Inhibrx, Inc.'s background, mission, and how it operates, explore: Inhibrx, Inc. (INBX): History, Ownership, Mission, How It Works & Makes Money

Understanding these aspects of Inhibrx, Inc.'s investor profile helps stakeholders gauge market sentiment and make informed decisions.

Inhibrx, Inc. (INBX) Institutional Ownership and Major Shareholders of Inhibrx, Inc. (INBX)

Institutional ownership in Inhibrx, Inc. (INBX) plays a significant role in the company's stock performance and overall strategy. Examining the top institutional investors, changes in ownership, and their potential impact provides valuable insights for investors.

Here’s a detailed look at Inhibrx, Inc. (INBX) major shareholders and their influence:

Top Institutional Investors:

Identifying the largest institutional investors in Inhibrx, Inc. (INBX) offers a glimpse into who holds significant stakes in the company. As of the latest data, the following are some of the top institutional holders:

• RA Capital Management, L.P.
• FMR LLC
• Vanguard Group Inc
• Blackrock Inc.
• BIOMED REALTY TRUST, INC.

These institutions manage substantial assets and their investment decisions can significantly influence Inhibrx, Inc. (INBX)'s stock price.

Changes in Ownership:

Recent changes in institutional ownership can indicate shifts in sentiment towards Inhibrx, Inc. (INBX). Increases in holdings may suggest confidence in the company's future prospects, while decreases could signal concerns. Monitoring these changes is crucial for understanding the evolving dynamics of investor interest.

Institutional investors frequently adjust their positions based on factors such as company performance, market conditions, and broader economic trends. Analyzing these changes over time provides valuable context for assessing Inhibrx, Inc. (INBX)'s attractiveness as an investment.

Impact of Institutional Investors:

The presence of large institutional investors can have several effects on Inhibrx, Inc. (INBX):

• Stock Price Stability: Significant institutional holdings can reduce volatility due to the large volumes they trade.
• Corporate Governance: Institutional investors often engage with company management to influence corporate governance and strategic decisions.
• Market Confidence: Their investment decisions can signal confidence (or lack thereof) to the broader market, influencing retail investor behavior.

Understanding these dynamics helps investors gauge the potential impact of institutional activity on Inhibrx, Inc. (INBX)'s stock performance.

For further insights into Inhibrx, Inc. (INBX)'s financial health, consider reading: Breaking Down Inhibrx, Inc. (INBX) Financial Health: Key Insights for Investors

Inhibrx, Inc. (INBX) Key Investors and Their Impact on Inhibrx, Inc. (INBX)

Understanding the investor profile of Inhibrx, Inc. (INBX) is crucial for assessing the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance through their holdings and actions. Recent activity in buying or selling stakes, as well as any activist involvement, provides valuable insights into market sentiment and future prospects. For additional background information, refer to Inhibrx, Inc. (INBX): History, Ownership, Mission, How It Works & Makes Money.

While specific, real-time details on all investors and their recent moves fluctuate and are often proprietary, we can discuss the types of investors and their potential impact based on available information and typical market behavior.

Institutional investors often hold significant stakes in biotech companies like Inhibrx, Inc. (INBX). These may include:

• Vanguard Group: Known for its index funds and ETFs, Vanguard often holds shares in a wide range of companies, reflecting broad market exposure.
• BlackRock: Another major asset manager with substantial holdings across various sectors, including healthcare and biotechnology.
• State Street Corporation: Similar to Vanguard and BlackRock, State Street manages vast assets and typically holds positions in numerous publicly traded companies.
• Fidelity Investments: A large mutual fund company that actively invests in the stock market.

Hedge funds may also have positions in Inhibrx, Inc. (INBX), seeking to capitalize on short-term price movements or long-term growth potential. Activist investors, who seek to influence company management and strategy, could also be relevant, although their presence and specific activities would need to be confirmed through filings and news reports.

The influence of these investors can manifest in several ways:

• Stock Price Volatility: Large purchases or sales by major investors can create significant price swings.
• Corporate Governance: Major shareholders can exert influence on board composition and executive compensation.
• Strategic Direction: Activist investors may push for specific changes in company strategy, such as mergers, acquisitions, or restructuring.

To get a clearer picture of investor influence, it's helpful to look at the ownership breakdown. While up-to-the-minute data requires real-time financial tools, here's a general idea of what ownership might look like:

Keep in mind that these percentages are illustrative and can change frequently due to market activity and reporting lags.

Inhibrx, Inc. (INBX) Market Impact and Investor Sentiment

Understanding investor sentiment and the resulting market reactions is crucial for assessing the potential future of any publicly traded company. For Inhibrx, Inc. (INBX), several factors influence how major shareholders and the broader market perceive the company.

As of April 14, 2025, Inhibrx Biosciences, Inc. has 219 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,030,744 shares.

Key investors in Inhibrx, Inc. include:

• Viking Global Investors Lp
• Sanofi
• Perceptive Advisors Llc
• BlackRock, Inc.
• HighTower Advisors, LLC
• Vanguard Group Inc
• Walleye Capital LLC
• Sofinnova Investments, Inc.
• Slotnik Capital, LLC
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares

Institutional ownership accounts for 76.89% of Inhibrx's total shares outstanding, with a total value of holdings amounting to $128 million.

Recent trading activity reveals the following trends:

• Increased Positions: 2,732,616
• Decreased Positions: 594,925
• Held Positions: 7,803,131
• Total Institutional Shares: 11,130,672

Russell Investments Group Ltd. acquired 54,345 shares of Inhibrx, Inc. during the 4th quarter of 2024, valued at approximately $837,000. This purchase represents about 0.38% ownership of Inhibrx by the end of the quarter.

Other hedge funds and institutional investors also made significant moves in Q4 2024:

• HighTower Advisors LLC acquired a new stake worth approximately $12,039,000.
• Slotnik Capital LLC acquired a new position worth $5,975,000.
• Geode Capital Management LLC purchased a new stake worth about $3,930,000.
• Bank of New York Mellon Corp acquired a new stake valued at about $792,000.
• Rangeley Capital LLC purchased a new position valued at about $761,000.

Approximately 82.46% of the stock is owned by hedge funds and other institutional investors.

Recent news that may influence investor sentiment includes:

• April 1, 2025: Inhibrx Biosciences announced the departure of its CSO and the appointment of a new CSO and President.
• March 17, 2025: Inhibrx reported its fourth quarter and fiscal year 2024 financial results.
• January 21, 2025: Inhibrx Biosciences announced preliminary data from the Phase 1 trial of ozekibart (INBRX-109) for the treatment of colorectal cancer.
• January 13, 2025: Inhibrx Biosciences announced a loan agreement with Oxford Finance.

The company's stock has experienced considerable volatility. On April 15, 2024, the share price was $34.74, but by April 14, 2025, it had declined to $11.88, representing a decrease of 65.80% over the year.

In terms of price performance, Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $34.75. On April 22, 2025, NASDAQ INBX opened at $11.38.

Inhibrx last released its earnings results on March 17, 2025, reporting an EPS of ($3.09) for the quarter, which missed analysts' consensus estimates of ($2.88) by ($0.21). The company's revenue for the quarter was $0.10 million.

In January 2024, Inhibrx announced the sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2 billion. As part of the agreement, Inhibrx shareholders would receive $30.00 per share in cash, one contingent value right (CVR) per share to receive $5.00 upon achieving a regulatory milestone, and one share of New Inhibrx for every four shares of Inhibrx common stock held.

On May 30, 2024, Sanofi completed its acquisition of Inhibrx, adding SAR447537 (formerly INBRX-101) to its rare disease pipeline. Former Inhibrx shareholders were entitled to receive $30.00 per share in cash and one CVR per share to receive an additional $5.00 upon the achievement of a regulatory milestone, representing a total equity value of approximately $1.7 billion.

Analyst perspectives vary. The consensus price target for Inhibrx Biosciences Inc. is $45.25, based on the ratings of 5 analysts. However, keep in mind that the most recent ratings are from 2022 and 2023. According to analysts, INBX price target is $15.00 USD with a max estimate of $15.00 USD and a min estimate of $15.00 USD.

For further insights into Inhibrx, Inc.'s financial standing, consider exploring this resource: Breaking Down Inhibrx, Inc. (INBX) Financial Health: Key Insights for Investors